Rasna Therapeutics, Inc. (RASP)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -379.62 Thousand USD | 1.12% |
| 2022 | 254.4 Thousand USD | -55.12% |
| 2021 | -247.5 Thousand USD | 55.39% |
| 2020 | -554.86 Thousand USD | 39.14% |
| 2019 | -912.92 Thousand USD | 77.55% |
| 2018 | -4.06 Million USD | 12.31% |
| 2017 | -4.53 Million USD | -7343.49% |
| 2016 | -62.22 Thousand USD | -271.35% |
| 2015 | -16.75 Thousand USD | 58.14% |
| 2014 | -40.03 Thousand USD | -646.92% |
| 2013 | -5360.00 USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -71.39 Thousand USD | -209.68% |
| 2024 Q1 | -124.73 Thousand USD | -141.1% |
| 2023 Q2 | -3.96 Million USD | -2771.29% |
| 2023 Q4 | -48.83 Thousand USD | 51.33% |
| 2023 Q1 | -138.14 Thousand USD | -345.68% |
| 2023 FY | - USD | 1.12% |
| 2023 Q3 | -100.32 Thousand USD | 97.47% |
| 2022 Q1 | -81.79 Thousand USD | -225.21% |
| 2022 Q4 | -30.99 Thousand USD | 75.76% |
| 2022 Q2 | -143.26 Thousand USD | -75.16% |
| 2022 FY | - USD | -55.12% |
| 2022 Q3 | -127.86 Thousand USD | 10.75% |
| 2021 Q4 | 65.32 Thousand USD | 201.16% |
| 2021 FY | - USD | 55.39% |
| 2021 Q1 | -154.62 Thousand USD | -16.55% |
| 2021 Q3 | -64.57 Thousand USD | 31.03% |
| 2021 Q2 | -93.62 Thousand USD | 39.45% |
| 2020 Q1 | -148.87 Thousand USD | -150.49% |
| 2020 Q4 | -132.67 Thousand USD | -43.96% |
| 2020 Q3 | -92.15 Thousand USD | 49.13% |
| 2020 Q2 | -181.17 Thousand USD | -21.7% |
| 2020 FY | - USD | 39.14% |
| 2019 Q2 | -259.84 Thousand USD | 34.4% |
| 2019 Q4 | -59.43 Thousand USD | 69.02% |
| 2019 FY | - USD | 77.55% |
| 2019 Q3 | -191.84 Thousand USD | 26.17% |
| 2019 Q1 | -396.07 Thousand USD | 2.64% |
| 2018 Q3 | -813.56 Thousand USD | 27.81% |
| 2018 Q2 | -1.12 Million USD | 43.52% |
| 2018 Q1 | -1.99 Million USD | -11.31% |
| 2018 FY | - USD | 12.31% |
| 2018 Q4 | -406.8 Thousand USD | 50.0% |
| 2017 Q1 | -1.39 Million USD | -0.5% |
| 2017 Q2 | -1.03 Million USD | 26.2% |
| 2017 Q4 | -1.79 Million USD | -43.81% |
| 2017 Q3 | -1.24 Million USD | -20.71% |
| 2017 FY | - USD | -7343.49% |
| 2016 Q3 | -55.19 Thousand USD | -2929.58% |
| 2016 Q4 | -1.39 Million USD | -2421.93% |
| 2016 Q2 | -1822.00 USD | 56.94% |
| 2016 FY | - USD | -271.35% |
| 2016 Q1 | -4231.00 USD | -333.95% |
| 2015 Q1 | -3672.00 USD | -7.06% |
| 2015 FY | - USD | 58.14% |
| 2015 Q4 | -975.00 USD | 68.51% |
| 2015 Q2 | -6559.00 USD | -78.62% |
| 2015 Q3 | -3096.00 USD | 52.8% |
| 2014 FY | - USD | -646.92% |
| 2014 Q1 | -14.21 Thousand USD | -90.5% |
| 2014 Q2 | -3491.00 USD | 75.44% |
| 2014 Q3 | -14.86 Thousand USD | -325.78% |
| 2014 Q4 | -3430.00 USD | 76.92% |
| 2013 FY | - USD | 0.0% |
| 2013 Q2 | -4305.00 USD | 0.0% |
| 2013 Q4 | -7463.00 USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 99.466% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 93.597% |
| SQZ Biotechnologies Company | -64.14 Million USD | 99.408% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 97.815% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 100.404% |
| Mesoblast Limited | -62.38 Million USD | 99.392% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 75.286% |
| Genus plc | 73.7 Million USD | 100.515% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 94.258% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 89.297% |
| Marizyme, Inc. | -34.28 Million USD | 98.893% |
| ContraFect Corporation | -64.99 Million USD | 99.416% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 95.672% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 91.613% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 72.919% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | 85.645% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | 83.664% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | 26.721% |
| Accustem Sciences Inc. | -3.74 Million USD | 89.867% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 99.213% |
| EV Biologics, Inc. | -1.26 Million USD | 70.041% |
| Q BioMed Inc. | -617.62 Thousand USD | 38.536% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 110.628% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 39.972% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | 83.383% |
| Biomind Labs Inc. | -1.03 Million USD | 63.306% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 103.843% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 94.699% |
| Skye Bioscience, Inc. | -13.54 Million USD | 97.198% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | 74.478% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -1418.48% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 90.227% |
| IMV Inc. | -35.52 Million USD | 98.931% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 97.608% |
| Curative Biotechnology, Inc. | -2.5 Million USD | 84.827% |
| GB Sciences, Inc. | -1.41 Million USD | 73.264% |
| Alpha Cognition Inc. | -9.7 Million USD | 96.089% |
| HST Global, Inc. | -5303.00 USD | -7058.589% |
| CSL Limited | 4.78 Billion USD | 100.008% |
| Halberd Corporation | -74.27 Thousand USD | -411.073% |
| Enzolytics Inc. | -2.12 Million USD | 82.111% |
| Resverlogix Corp. | -11.74 Million USD | 96.767% |
| Affymax, Inc. | -14.29 Million USD | 97.344% |
| SYBLEU INC | -141.57 Thousand USD | -168.148% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 87.606% |
| argenx SE | -216.02 Million USD | 99.824% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 99.314% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 131.193% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | 74.674% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 200.205% |
| AVAX Technologies, Inc. | -6.11 Million USD | 93.79% |
| Zenith Capital Corp. | -8.6 Million USD | 95.589% |
| Genscript Biotech Corporation | -248.71 Million USD | 99.847% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -2079.094% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | 84.483% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -115.663% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 99.042% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 86.875% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | 63.718% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 5745.747% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | 78.307% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | 80.238% |
| BioStem Technologies, Inc. | -7.55 Million USD | 94.974% |
| ONE Bio Corp. | 13.61 Million USD | 102.789% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -109.633% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | 81.545% |
| Agentix Corp. | -1.37 Million USD | 72.326% |
| LadRx Corporation | 412.28 Thousand USD | 192.078% |
| Cell Source, Inc. | -4.27 Million USD | 91.115% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -3.376% |
| Regen BioPharma, Inc. | 1.46 Million USD | 125.896% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | 59.483% |
| NovAccess Global Inc. | -1.03 Million USD | 63.315% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 104.288% |
| Itoco Inc. | -1.86 Million USD | 79.689% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 65.984% |
| Kadimastem Ltd | -2.62 Million USD | 85.535% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -58.737% |
| CytoDyn Inc. | -18.02 Million USD | 97.894% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -380.355% |
| Mobile Lads Corp. | -2.24 Million USD | 83.061% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -3004.26% |
| Qrons Inc. | -40.08 Thousand USD | -847.132% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | 21.837% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 171.975% |
| Rebus Holdings, Inc. | -951 Thousand USD | 60.082% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | 64.255% |
| International Stem Cell Corporation | 202 Thousand USD | 287.931% |
| Bioxytran, Inc. | -3.82 Million USD | 90.063% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -621.163% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | 84.58% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 98.942% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -743.6% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 86.135% |
| Neutra Corp. | -181.24 Thousand USD | -109.449% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 98.117% |
| PureTech Health plc | -11.62 Million USD | 96.735% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 98.117% |
| IXICO plc | -707 Thousand USD | 46.306% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 95.06% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 99.215% |
| CSL Limited | 4.73 Billion USD | 100.008% |
| Cellectis S.A. | -92.63 Million USD | 99.59% |